Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.
Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Reményi P, Socié G, van Gorkom G, Labussière-Wallet H, Huang XJ, Rubio MT, Byrne J, Craddock C, Griškevičius L, Ciceri F, Mohty M. Nagler A, et al. Among authors: remenyi p. Bone Marrow Transplant. 2023 Jul;58(7):791-800. doi: 10.1038/s41409-023-01980-y. Epub 2023 Apr 12. Bone Marrow Transplant. 2023. PMID: 37045942
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, Kulagin A, Busca A, Rodríguez AB, Reményi P, Schmid C, Brissot E, Sanz J, Bazarbachi A, Giebel S, Ciceri F, Mohty M. Nagler A, et al. Among authors: remenyi p. J Hematol Oncol. 2023 May 29;16(1):58. doi: 10.1186/s13045-023-01450-4. J Hematol Oncol. 2023. PMID: 37248463 Free PMC article.
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature.
Robin M, Gras L, Koster L, Saccardi R, Finke J, Forcade E, Rovira M, Kobbe G, Reményi P, Apperley J, Smaranda A, Bay JO, Casper J, de Wreede LC, Giebel S, Grillo G, Heras I, Potter V, Tischer J, Trociukas I, Nachbaur D, Drozd-Sokolowska J, Raj K, Gurnari C, Yakoub-Agha I, Onida F, Scheid C, McLornan D. Robin M, et al. Among authors: remenyi p. Bone Marrow Transplant. 2023 Aug;58(8):942-945. doi: 10.1038/s41409-023-01991-9. Epub 2023 Apr 25. Bone Marrow Transplant. 2023. PMID: 37185613 No abstract available.
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler A, Labopin M, Dholaria B, Blaise D, Bondarenko S, Vydra J, Choi G, Rovira M, Reményi P, Meijer E, Bulabois CE, Diez-Martin JL, Yakoub-Agha I, Brissot E, Spyridonidis A, Sanz J, Patel A, Arat M, Bazarbachi A, Bug G, Savani BN, Giebel S, Ciceri F, Mohty M. Nagler A, et al. Among authors: remenyi p. Br J Haematol. 2023 Jun;201(6):1169-1178. doi: 10.1111/bjh.18765. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949658
Bone marrow transplantation in non-malignant disorders.
Kriván G, Timár L, Goda V, Réti M, Reményi P, Masszi T. Kriván G, et al. Among authors: remenyi p. Bone Marrow Transplant. 1998 Dec;22 Suppl 4:S80-3. Bone Marrow Transplant. 1998. PMID: 9916644
102 results